World-renowned experts across infectious diseases, vaccines, and dermatology to advise Piezo on advancing its energy-based delivery platform and internal programs to the clinic

Publication describes a new delivery platform (Piezopen) that augments gene expression and immunogenicity to a "naked" mRNA vaccine comparable to benchmark LNP formulations
Piezopen delivers diverse cargos (mRNA, saRNA, circRNA, and DNA) and across species (mice, rats, human skin)
Potential to improve dosing, reactogenicity, durability, cost, and manufacturing hurdles of mRNA vaccines by eliminating LNPs

Piezo is developing a simple, affordable, and scalable platform designed for rapid, safe, and efficient delivery of nucleic acid medicines, including RNA/DNA vaccines, therapeutic proteins, and dermal gene therapies
Invented by Georgia Tech researchers, Piezo launches with $2 million in seed funding from Open Philanthropy